Novo Nordisk’s semaglutide misses in closely-watched Alzheimer’s trials
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1 agonist failed to delay disease progression in patients in two …
STAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression
Two trials testing the Novo Nordisk weight loss drug semaglutide in Alzheimer’s disease failed, the company said Monday, showing the medicine did not slow the progression of the condition versus placebo. Studying semaglutide — the key ingredient in the blockbusters Ozempic and Wegovy — in Alzheimer’s was always seen as a long shot, even as […]
UBS sees 60% more upside in Shaily Engineering after a massive 700% rally in two years. Here’s why
UBS has initiated coverage of Shaily Engineering Plastics with a ‘Buy’ rating and a target price of ₹4,000, indicating a 60% upside. The firm highlights Shaily’s patented technology and strong market position for GLP-1 therapies, estimating substantial revenue growth and a 75% EPS CAGR by FY28.
Insulin Doctor: This Is The First Sign Of Dementia! The Shocking Link Between Keto & Brain Decline!
No.1 Keto Doctor DR. ANNETTE BOSWORTH reveals how to reverse insulin resistance, cut belly fat, avoid early dementia, why eating late spikes glucose, and the sardine-only reset for ketosis. Dr Annette Bosworth, commonly known as Dr Boz, is an internal medicine doctor with over 2 decades of experience, who helps reverse medical problems through healthy […]
Study finds GLP-1 drugs improve strength and reverse aging biology in mice
Researchers showed that GLP-1 receptor agonism counteracts aging across multiple organs in mice, improving strength and reversing molecular aging signatures without meaningful effects on body weight. These benefits depended largely on hypothalamic GLP-1R signaling and closely mirrored the anti-aging patterns produced by rapamycin.
Could Trump do for Branded Expensive Drugs What He Just Did for GLP-1s?
The Trump administration’s new deal lowers prices and expands access to GLP-1 drugs, but experts argue far broader reforms are needed to address high prescription drug costs overall. The post Could Trump do for Branded Expensive Drugs What He Just Did for GLP-1s? appeared first on MedCity News.
Better Than Ozempic? New Oxytocin Combination Could Eliminate Side Effects
In addition to reducing hunger, popular weight-loss drugs also affect reward processing and motivated behaviors. New research is offering a clearer picture of how medications that target the glucagon-like peptide-1 (GLP-1) system influence brain networks involved in nausea, thirst, and reward-driven behaviors. These new results were recently shared at Neuroscience 2025, the annual meeting of […]
Eli Lilly to Launch a GLP-1 Pill to Rival Ozempic, but There’s a Catch
The new drug will target weight loss for people with obesity and type 2 diabetes.
Daily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial finds
A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1 – Seeking Alpha
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1 Seeking Alpha High-stakes Novo Nordisk Alzheimer’s studies could yield answers on GLP-1 benefit Reuters Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results statnews.com Key facts: Novo Nordisk trials Rybelsus for cognitive decline; analysts see stable growth TradingView Novo Nordisk Will Soon Reveal Whether Its GLP-1 […]